Cell-of-origin and genetic drivers define advanced bladder cancer subtypes and potential therapeutic response in mouse models
Ester Munera-MaravillaiD, Mercedes Pérez-EscavyiD, Carolina RubioiD, Cristina SegoviaiD, Iris LodewijkiD, Sandra P NunesiD, Álvaro Martín de BernardoiD, Ignacio Arévalo ReinaiD, Esther Montesinos, Lucía MoralesiD, Víctor G. MartíneziD, Ainara Álvarez-Prada, Mónica Martínez-Fernández, Marta DueñasiD, Jesús María ParamioiD, Cristian Suárez-CabreraiD
Abstract
Bladder cancer (BC) remains a major clinical challenge owing to its high recurrence, limited treatment options, and molecular heterogeneity. Despite recent therapeutic advances, prognosis remains poor, and resistance is frequent, underscoring the need for improved experimental models to study tumorigenesis and therapeutic response. A key limitation of advanced BC research is the scarcity of in vivo models that accurately reflect invasive disease, with even fewer capturing the complexity of metastasis. To investigate how the cell-of-origin and specific combinations of driver mutations influence in bladder tumorigenesis, we developed and characterized four genetically engineered mouse models of advanced BC by targeting two combinations of tumor suppressor genes (Pten and Trp53, or Pten, Trp53, Rb1, and Rbl1) in basal or suprabasal urothelial cells through intravesical of Cre-adenovirus delivery. Loss of the retinoblastoma family reduced cancer-specific survival and was associated with more differentiated carcinomas. In both genetic backgrounds, luminal-derived tumors developed earlier but showed fewer metastatic events. Histopathological and transcriptomic analyses revealed that these tumors resemble human basal-squamous and stroma-rich subtypes, sharing regulatory networks and activated signaling pathways with human invasive tumors. Notably, tumors lacking retinoblastoma family genes exhibited increased immune infiltration, reinforcing the value of these models for diverse preclinical applications. To overcome detection and latency limitations, we established tumor-derived cell lines and generated syngeneic graft models. These were validated as preclinical platforms, exhibiting therapeutic responses to CDK4/6 inhibition and anti-PD-L1 immunotherapy. Our findings highlight the value of these novel models for studying BC progression and evaluating emerging therapeutic strategies in immunocompetent settings.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- 10th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Intrinsic higher potency of basal urothelial cells to intermediate and umbrella cells as the cell of origin for bladder cancer
Chuan Yu, Nicholas Chu, … Zhu A. Wang·bioRxiv·Jun 28, 2025
- Syngeneic model of carcinogen-induced tumor mimics basal/squamous, stromal-rich, and neuroendocrine molecular and immunological features of muscle-invasive bladder cancer
S. D. Shah, B. M. Gillard, … B. A. Foster·Frontiers in OncologyPeer-reviewed·Feb 3, 2023
- Targeting CXCR4-expressing TAMs in muscle-invasive bladder cancer to enhance tumor control after immunotherapy
Emma Desponds, Hajar El Ahanidi, … Grégory Verdeil·bioRxiv·Mar 21, 2025
- Heterogeneous Effects of Src Inhibition on Determinants of Metastasis in Preclinical Models of Human Bladder Cancer
Adam K. Aragaki, Bryan Wehrenberg, … David James McConkey·bioRxiv·Nov 9, 2024
- Modeling adaptive therapy in non-muscle invasive bladder cancer
M. C. Ferrall-Fairbanks, G. J. Kimmel, … P. M. Altrock·bioRxiv·Nov 7, 2019
- Integrated molecular and pharmacological characterization of patient-derived xenografts from bladder and ureteral cancers identifies new potential therapies.
H. Lang, C. Beraud, … T. Massfelder·Frontiers in OncologyPeer-reviewed·Aug 11, 2022